Background/objectives: The development of psoriasis while on tumor necrosis factor inhibitors (TNFi) is a paradoxical effect of agents that treat psoriasis. There is a paucity of data available on this entity in juvenile idiopathic arthritis (JIA). Our objectives were to determine the prevalence of TNFi-induced psoriasis in patients with JIA at two pediatric centers, and psoriasis response to therapeutic modifications.
Methods: We performed retrospective chart review on patients with JIA treated with TNFi (adalimumab, etanercept, infliximab) who developed psoriasis. TNFi-induced psoriasis was defined as an incident diagnosis of psoriasis after starting a TNFi. Patients with personal histories of psoriasis prior to TNFi therapy were excluded. Following diagnosis, responses to medication changes were defined based on physician assessments.
Results: Nine of 166 (5.4%) patients on TNFi for JIA were diagnosed with TNFi-induced psoriasis. All cases were female. One had a family history of psoriasis. The median age was 10 (range 2-16) years. Five (55%) patients experienced scalp psoriasis, including four (44%) with alopecia. Two (22%) patients achieved significant improvement after switching to different classes of biologic agents, while three (33%) patients had significant improvement following discontinuation of biologic therapy. One of five patients who switched to a different TNFi had complete resolution, while four had worsening symptoms or partial improvement.
Conclusions: Our findings demonstrate the prevalence of TNFi-induced psoriasis in JIA at two centers. Though larger studies are needed, our data suggest discontinuation of TNFi or biologic class switching should be considered as treatment strategies in select patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.13859 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of and genes: a gene expression study.
Front Immunol
November 2023
Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Background: In psoriatic arthritis (PsA), the primary goal of treatment is clinical remission. This study aimed to characterize the molecular profile underlying the induced clinical remission in patients with PsA, comparing the remission state and the healthy condition.
Methods: Whole blood transcriptomic analysis was performed on groups of 14 PsA patients in TNFi-induced clinical remission (DAPSA ≤ 4), 14 PsA patients with active disease (DAPSA > 14), and 14 healthy controls (HCs).
Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
J Rheumatol
August 2022
P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Article Synopsis
- The study aimed to assess how tumor necrosis factor inhibitor (TNFi) therapies and the use of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) affect the occurrence of psoriasis in children with conditions like inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic nonbacterial osteomyelitis (CNO).
- Conducted from 2008 to 2020, the research involved 5088 children and analyzed the incidence rates of psoriasis related to TNFi and DMARD use, utilizing Poisson regression to compute incidence rate ratios.
- Results showed that children exposed to adalimumab (ADA) had the highest incidence rate of developing psoriasis, while those on TNFi
Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris.
J Am Acad Dermatol
July 2020
Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Background: Tumor necrosis factor-α inhibitor (TNFi)-induced psoriasis is a paradoxic reaction characterized by the development of a psoriasiform rash that mimics idiopathic psoriasis subtypes both clinically and histologically. Few studies have investigated the histologic features of TNFi-induced psoriasis skin lesions, and most of these are limited by inclusion of few specimens.
Objective: We aimed to characterize histologic features of TNFi-induced psoriasis and identify histologic differences between TNFi-induced psoriasis and idiopathic psoriasis.
Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Pediatr Dermatol
September 2019
Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Background/objectives: The development of psoriasis while on tumor necrosis factor inhibitors (TNFi) is a paradoxical effect of agents that treat psoriasis. There is a paucity of data available on this entity in juvenile idiopathic arthritis (JIA). Our objectives were to determine the prevalence of TNFi-induced psoriasis in patients with JIA at two pediatric centers, and psoriasis response to therapeutic modifications.
View Article and Find Full Text PDFTNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
J Am Acad Dermatol
December 2020
Cleveland Clinic, Cleveland, Ohio. Electronic address:
Background: Tumor necrosis factor-α (TNF-α) inhibitor (TNFI)-induced psoriasis remains poorly understood despite having been described 15 years ago. As TNFIs often provide life-changing patient benefits, understanding effective treatments for TNFI-induced psoriasis is important.
Objective: We characterized a cohort of patients with TNFI-induced psoriasis whose psoriasis was specifically diagnosed and managed or comanaged by dermatologists at a single tertiary care institution over a 10-year period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!